External validation of a prognostic score predicting overall survival for patients with brain metastases based on extracranial factors

Victor Lewitzki a,⇑, Rainer J. Klement b, Sebastian Hess a, Rebekka Kosmala a, Carsten Nieder c,d, Michael Flentje a

a University of Würzburg, Department of Radiation Oncology, Josef-Schneider-Str. 11, 97080 Würzburg, Germany
b Department of Radiation Oncology, Leopoldina Hospital Schweinfurt, 97422 Schweinfurt, Germany
c Department of Clinical Medicine, Faculty of Health Science, UiT The Arctic University of Norway, Tromsø, Norway
d Department of Oncology and Palliative Medicine, Nordland Hospital Trust, 8092 Bodø, Norway

Purpose: The aim of our study was an external validation of the extracranial prognostic score predicting survival of patients with brain metastases receiving cranial irradiation on data from a single institution.

Materials and methods: A retrospective analysis of 524 patients with brain metastases treated with cranial radiotherapy in a single tertiary center was performed. Three predictive scores were calculated and assessed for their ability to discriminate prognostic groups: (i) The Recursive Partitioning Analysis (RPA) score (available for 524 patients); (ii) the Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) score (464 patients); (iii) the extracranial score (EC-S) developed by Nieder et al. which is based on serum albumin, lactate dehydrogenase (LDH) and the number of extracranial organs involved (157 patients). Discrimination of each score was assessed by Gönen & Heller’s concordance probability estimate (CPE). The calibration was checked by comparing median survival estimates of each risk group with the corresponding values of the datasets from which the scores were derived. Finally, a multivariable Cox regression model was built by using the least absolute shrinkage and selection operator on a large number of variables including all three scores.

Results: With a CPE = 0.626 ± 0.022, the EC-S had the best discriminatory power. The EC-S also appeared to be better calibrated and had the best ability to separate patients with a very poor prognosis: patients with combination of low albumin, elevated LDH and more than 1 extracranial organ with metastatic involvement had a median survival time of only 0.6 months (CI95% 0.1–1.1) and a hazard ratio for death of 6.36 (2.67–15.14) compared to patients with no extracranial metastases and normal levels of albumin and LDH. In the multivariable Cox model serum albumin, LDH, treatment modality, DS-GPA and EC-S were retained as prognostic factors. An ad hoc combination of both DS-GPA and EC-S into a new score was possible for 134 patients and indicated a slightly better discrimination (CPE = 0.636 ± 0.023) than either DS-GPA or EC-S alone.

Conclusions: This study provides an independent validation of the prognostic EC-S which was the best prognostic model for defining the patients who obviously did not benefit from radiation therapy of brain metastases in terms of overall survival. The combination of the EC-S with the established DS-GPA score resulted in a slight increase in discriminatory ability. The new EC-GPA score needs further validation in larger patient cohorts.

1. Introduction

The development of appropriate patient selection criteria for tumor specific treatment including chemo- and radiotherapy (RT) is the cornerstone of modern precision oncology. With regard to life-threatening conditions such as brain-disseminated cancer it is widely believed and anticipated that aggressive antitumor treatment should be started as soon as possible to prolong survival and maintain quality of life. However, it has long been recognized that some patients will not derive any profit from active treatment while other will do. In order to discriminate those patients...
potentially benefitting from antitumor therapy, several prognostic scores such as the RTOG Recursive Partitioning Analysis (RPA) [1] score or the Graded Prognostic Assessment (GPA) score [2] were developed and validated [3,4]. Although offering a possibility to separate the survival curves, i.e., identifying patient groups with better and worse prognosis, these models have not sufficient predictive ability for deciding which patients will not derive sufficient benefit from brain RT, which is important within the context of counselling patients about their prognosis and treatment options. It is known that several widely available and cheap blood tests such as albumin and lactate dehydrogenase (LDH) can be used as surrogate parameters in survival prediction [5,6]. The number of extracranial organ systems involved has also been found to be an independent and highly significant predictor of overall survival [7,8]. The combination of those three parameters was used by Nieder et al. to develop a simple extracranial score (EC-S) as a reasonable addition to the aforementioned intracranial prognostic factors helping to identify the patients with brain metastases with very bad prognosis in whom best supportive care could be the best choice [9]. The main goal of this study was an independent validation of the EC-S as a possible tool for predicting very limited survival and to compare it with the RPA and disease-specific GPA (DS-GPA) scores.

2. Materials and methods

We extracted all available patient records referring to a diagnosis of brain metastases from the clinical RT software Mosaiq© from the Department of Radiation Oncology at the University hospital Wuerzburg. Overall survival (OS) data from 524 patients treated between 04.02.2008 and 08.11.2017 were available. Brain MRI was obligatory as a part of staging for patients with primarily

Table 1
Patient characteristics (n = 524). Abbreviations used in the table: renal cell carcinoma (RCC), Karnofsky performance score (KPS), whole brain radiotherapy (WBRT), radiotherapy (RT).

| Parameter                                      | N (whole) | EC-S available | % (whole) | EC-S available |
|------------------------------------------------|-----------|----------------|-----------|----------------|
| Gender                                         |           |                |           |                |
| Female                                         | 242       | 64             | 46        | 41             |
| Male                                           | 282       | 93             | 54        | 59             |
| Age (years)                                    | Median 63 | Median 63      | Range (20–92) | Range (21–86) |
| Primary                                        |           |                |           |                |
| Lung                                           | 270       | 87             | 51        | 55             |
| Breast                                         | 66        | 7              | 13        | 5              |
| RCC                                            | 22        | 7              | 4         | 5              |
| Melanoma                                       | 74        | 34             | 14        | 22             |
| Head and neck                                  | 6         | 0              | 1         | 0              |
| GI                                             | 37        | 7              | 7         | 5              |
| CUP                                            | 19        | 6              | 4         | 4              |
| other                                          | 30        | 9              | 6         | 6              |
| KPS                                            |           |                |           |                |
| KPS >70%                                       | 228       | 70             | 43        | 44             |
| KPS ≤70%                                       | 297       | 87             | 57        | 56             |
| RPA class                                      |           |                |           |                |
| 1                                              | 133       | 34             | 25        | 22             |
| 2                                              | 262       | 86             | 50        | 55             |
| 3                                              | 129       | 37             | 25        | 24             |
| DS-GPA class                                   |           |                |           |                |
| 1                                              | 190       | 61             | 41        | 43             |
| 2                                              | 154       | 38             | 33        | 27             |
| 3                                              | 92        | 26             | 20        | 18             |
| 4                                              | 28        | 16             | 6         | 11             |
| EC-S                                           |           |                |           |                |
| 0                                              | 15        |                | 10        |                |
| 1                                              | 69        |                | 44        |                |
| 2                                              | 60        |                | 38        |                |
| 3                                              | 13        |                | 8         |                |
| Molecular target with therapeutic relevance present |           |                |           |                |
| Yes                                            | 97        | 30             | 19        | 19             |
| No                                             | 424       | 126            | 81        | 81             |
| Primary controlled                             |           |                |           |                |
| Controlled                                     | 305       | 83             | 58        | 53             |
| Not controlled                                 | 219       | 74             | 42        | 47             |
| Number of brain metastases                    |           |                |           |                |
| One                                            | 143       | 40             | 27        | 26             |
| Two or three                                   | 107       | 34             | 20        | 22             |
| Multiple                                       | 274       | 83             | 52        | 53             |
| Extracranial metastases                        |           |                |           |                |
| No                                             | 101       | 23             | 19        | 15             |
| Single organ                                   | 152       | 40             | 29        | 26             |
| Multiple                                       | 271       | 94             | 52        | 60             |
| Treatment modality                             |           |                |           |                |
| Surgery + adjuvant RT or stereotactic radiosurgery | 103     | 51             | 20        | 32             |
| WBRT and others                                | 421       | 106            | 93        | 68             |
non-metastasized lung cancer and malignant melanoma. In other cases the clinical symptoms of brain metastases prompted cranial imaging. In our clinic the vast majority of tumor patients receive their treatment recommendation after discussion in interdisciplinary tumor boards. Further diagnostic work-up was performed according to the advice of the tumor board and based basically on national guidelines. Prognostic scores for each patient were determined as originally described [12]. For calculating the EC-S one point was counted for each elevated LDH, decreased albumin and more than one extracranial site of metastatic involvement, so that the final score ranged from 0 to 3 (3 indicating the worst prognosis) [8].

Elevated LDH was defined as above 250 U/l, and decreased albumin was defined as below 3.5 g/l according to the normal levels of the local laboratory. LDH and albumin measurements were only considered if taken within 2 weeks before the first fraction of RT. Since both blood tests are not mandatory in our radiotherapy department, only 157 out of 524 extracted patient records contained information on all 3 extracranial prognostic parameters. In contrast, the RPA score could be computed for all, and DS-GPA score for 466 patients. Only 134 cases had both DS-GPA and EC-S available. An overview of all relevant patient characteristics is given in Table 1.

Actuarial survival from the first day of whole-brain (WB) or other RT was calculated using the Kaplan-Meier method and compared between different groups with the Log-rank test. Discrimination of each score was assessed by Gönen & Heller’s concordance probability estimate (CPE) for the Cox model [10]. The concordance probability is a general measure of discriminatory power of a non-linear statistical model, with a probability of 0.5 indicating random discrimination and 1 perfect discrimination. The calibration (external validity) was checked by comparing median survival estimates of each risk group with the corresponding values of the datasets from which the scores were derived [11]. To determine the most important prognostic factors in multivariable analysis, Cox regression was used. The following covariates from Table 1 were judged as putatively important prognostic factors: treatment modality (surgery + adjuvant RT or stereotactic radiosurgery/WBRT and others), age (<65/>65 years as used in the RPA score), gender, baseline Karnofsky performance score (KPS; <70/>70), primary tumor type (8 strata in total), presence of a molecular target with therapeutic relevance (yes/no), the number of extracranial organs involved (0/1/>1), number of brain metastases (1/2 or 3/>3), serum albumin (normal/decreased), LDH (normal/elevated), RPA score, DS-GPA score and EC-S. Those variables were available for 140 patients of which 119 had died. Given the large number of covariates, these selected variables were then used to build a new predictive model. For calculating the EC-S one point was counted for each elevated LDH, decreased albumin and more than one extracranial site of metastatic involvement, so that the final score ranged from 0 to 3 (3 indicating the worst prognosis) [8].

The following covariates from Table 1 were judged as putatively important prognostic factors: treatment modality (surgery + adjuvant RT or stereotactic radiosurgery/WBRT and others), age (<65/>65 years as used in the RPA score), gender, baseline Karnofsky performance score (KPS; <70/>70), primary tumor type (8 strata in total), presence of a molecular target with therapeutic relevance (yes/no), the number of extracranial organs involved (0/1/>1), number of brain metastases (1/2 or 3/>3), serum albumin (normal/decreased), LDH (normal/elevated), RPA score, DS-GPA score and EC-S. Those variables were available for 140 patients of which 119 had died. Given the large number of covariates, these selected variables were then used to build a new predictive model. For calculating the EC-S one point was counted for each elevated LDH, decreased albumin and more than one extracranial site of metastatic involvement, so that the final score ranged from 0 to 3 (3 indicating the worst prognosis) [8].
Given the selection of both DS-GPA and EC-S into the final Cox model, we heuristically combined both scores into a new “EC-GPA” score with 4 categories (Table 4). Stratification of the 134 patients for which the new EC-GPA combination could be calculated resulted in a clear separation of the survival curves (Fig. 3). The hazard ratios of EC-GPA classes 1, 2 and 3 compared to class 0 were 4.84 (95% CI 1.42–16.46), 9.26 (2.83–29.97) and 31.64 (8.36–119.76). Furthermore, with a CPE = 0.6355 ± 0.0230 the discrimination between the four prognostic groups was slightly increased compared to the EC-S alone (CPE = 0.6258 ± 0.0220).
4. Discussion

A problem of proper patient and/or therapy selection has not lost its importance since the beginning of local therapy of brain metastasis. Selecting patients who have a chance to derive any benefit from antitumor treatment is a prerequisite for omitting unneeded treatment of those who have very limited survival prognosis.

Some discouraging results of more aggressive local treatment of brain metastases [14,15] challenged clinicians and statisticians. Several methodologies on the way to prognostic tools for discrimination of patient populations benefiting from more aggressive treatment were developed [2,16] and validated [17–19].

Despite the validation of the RPA score we believe that it is not helpful in answering any of the above questions. Sperduto et al. modified the original GPA score obviously due to the need to better stratify patients with brain metastases. The DS-GPA and finally Lung-molGPA [20] and Melanoma-molGPA [21] scores were developed and externally validated [19]. Nevertheless, even these most recent scores have limited ability of reliably predicting individual patient prognosis, sometimes classifying several long term survivors into the group with the worst prognosis and vice versa [21].

The role of extracranial factors such as performance status, extent of extracranial metastases or control of the primary tumor provided some additional valuable information about an individual’s prognosis [22]. A further refinement of the individual prognosis within the group of patients with very limited survival was possible after inclusion of such widely available and cheap biochemical surrogate parameters such as LDH and albumin [6].

The application of the EC-S to our data yielded similar results as in the original derivation study by Nieder et al. [6]. First, with the exception of the fairly good prognosis class 1, the EC-S appeared well calibrated with median OS differences between our data and the derivation data not larger than 1.1 months (Table 2). Second, the EC-S had the highest discriminatory power as judged by Gönen & Heller’s CPE. Third, the EC-S performed better than the RPA or DS-GPA score in separating the group of patients with very poor prognosis. However, in contrast to the DS-GPA score, the EC-S was not able to separate the two groups of patients with a good and fairly good prognosis in our data. This indicates some miscalibration of the model underlying the EC-S for patients with more favorable prognoses, so that survival predictions for new patients are not necessarily reliable.

In building a multivariable prognostic Cox regression model on our dataset, the RPA score was not selected as a prognostic factor, while both the DS-GPA and EC-S were. Due to these findings we pursued the idea of combining these two scores. We built 4 classes in the collective of 134 patients with both known DS-GPA and EC-S as displayed in Table 4. Application of the new combined score (EC-GPA) resulted in a clear separation of the survival curves (Fig. 3) and yielded slightly better discrimination between prognostic groups than either the DS-GPA or EC-S alone, although the CPEs of the EC-S and EC-GPA scores overlap within their uncertainties due to the small sample size. We believe that, although acquired heuristically, the EC-GPA score combination could be a good prognostic tool which should be evaluated in future studies using larger combined or independent datasets.

It is obvious that the paradigm of reserving stereotactic radiosurgery for treating patients with the most favorable prognoses changed over time. Low toxicity and wide availability of stereotactic radiosurgery led to its more frequent application and omission of WBRT [23] despite still controversial evidence for a clinical benefit and clear concerns from detailed analysis of available randomized trials [24,25]. Prognostic scores were not analyzed in the EORTC 22952–26001 trial, and only the RPA-score was used in the trial of Yamamoto et al. The stratification according to GPA score in the secondary analysis of Aoyama et al. demonstrated clear benefit of WBRT in combination with stereotactic radiosurgery in the group with best prognosis also in terms of OS.

Since the publication of the QUARTZ-trial there is a good level of evidence that in preselected patients the use of very hypofractionated WBRT has a limited effect on OS and quality of life [26]. Due to several limitations of the trial such as intention-to-treat analysis (ca. 20% of patients in the WBRT group did not receive WBRT), a low treatment dose of 20 Gy, an obvious negative selection of patients in both groups and more aggressive antitumor therapy in the control arm there are still some questions about its practice changing role. Despite the main conclusion of this trial, younger patients did derive a clear benefit from WBRT in terms of overall survival. GPA was not a significant variable in the survival analysis, probably because of the limited number of patients with a high score and limited statistical power to address this research question.
Our study shows that incorporation of extracranial factors into a prognostic model significantly improves discriminatory power. Nevertheless, our study has some limitations due to its retrospective nature and limited sample size, especially for the subset of patients for which the EC-S could be calculated. Furthermore, it was not planned a priori to develop a new prognostic score – the combination of DS-GPA and EC-S was rather a data-driven heuristic approach for improving the discrimination of various patient groups with distinctly different prognoses. Due to the limited data quality associated with the retrospective nature of this study, the ad-hoc definition of the combined EC-GPA score should be seen as a limitation. We prefer to consider the EC-GPA score as a hypothetical possible way for further refinement of both the DS-GPA and EC-S that should however be evaluated in future studies.

5. Conclusions

In conclusion, our study provides an independent validation of the prognostic EC-S developed by Nieder et al. [6]. Their prognostic model which is based solely on extracranial factors appeared to have a higher external validity than both the RPA and DS-GPA scores when applied to the unselected patients from our hospital. It was also the best prognostic model for defining the patients who obviously did not benefit from RT of brain metastases at least in terms of OS. The combination of the EC-S with the established DS-GPA score resulted in a slight gain of discriminatory ability. Further validation of the EC-S and the new EC-GPA score will be pursued in an ongoing analysis of combined patient cohorts from different tertiary care centers.

Conflict of interest

None.

References

[1] Gaspar L, Scott C, Rotman M, Ashbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745–51.

[2] Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008;70:510–4. https://doi.org/10.1016/j.ijrobp.2007.06.074.

[3] Nieder C, Mehta MP, Geinitz H, Grossu AL. Prognostic and predictive factors in patients with brain metastases from solid tumors: a review of published nomograms. Crit Rev Oncol Hematol 2018;126:13–8. https://doi.org/10.1016/j.critrevonc.2018.03.018.

[4] Nieder C, Mehta MP. Prognostic indices for brain metastases—usefulness and challenges. Radiat Oncol. 2009;4:10. https://doi.org/10.1186/1748-717X-4-10.

[5] Feliu J, Jimenez-Gordo AM, Madero R, Rodriguez-Azucoar JR, Espinosa E, Castro J, et al. Development and validation of a prognostic nomogram for terminally ill cancer patients. J Natl Cancer Inst 2011;103:1613–20. https://doi.org/10.1093/jnci/djr388.

[6] Nieder C, Marienhagen K, Dalhaug A, Aandahl G, Haukland E, Pawinski A. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704–10.

[7] Gaspar LE, Scott C, Murray K, Curran W. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 2000;47:1001–6.

[8] Videtic GM, Adelstein DJ, Melkham TM, Rice TW, Stevens GH, Lee SY, et al. Validation of the RTOG recursive partitioning analysis (RPA) classification for small-cell lung cancer-only brain metastases. Int J Radiat Oncol Biol Phys 2007;67:240–3. https://doi.org/10.1016/j.ijrobp.2006.08.019.

[9] Nieder C, Hintz M, Dehlke O, Bilger A, Grossu AL. Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA). Radiat Oncol 2017;12:107. https://doi.org/10.1186/s13014-017-0844-5.

[10] Sperduto PW, Yang T, Beal K, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (lung-molGPA). JAMA Oncol 2017;3:827–31. https://doi.org/10.1001/jamaoncol.2016.3834.

[11] Sperduto PW, Jiang W, Brown PD, Brausean P, Sneed P, Watson DA, et al. Estimating survival in melanoma patients with brain metastases: an update of the graded prognostic assessment for melanoma using molecular markers (melanoma-molGPA). Int J Radiat Oncol Biol Phys 2017;99:812–6. https://doi.org/10.1016/j.ijrobp.2017.06.254.

[12] Nieder C, Norum J, Dalhaug A, Aandahl G, Engjahlriker B. Best supportive care in patients with brain metastases and adverse prognostic factors: development of improved decision aids. Support Care Cancer 2013;21:2671–8. https://doi.org/10.1007/s00520-013-2146-5.

[13] Yamamoto M, Serizawa T, Shuto T, Akahane A, Higuchi Y, Kawagishi J, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLG0901): a multi-institutional prospective observational study. Lancet Oncol 2014;15:387–95. https://doi.org/10.1016/s1470-2045(14)70063-0.

[14] Ayonama H, Tago M, Shirato H. Japanese Radiation Oncology Study Group I. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol 2015;1:457–64. https://doi.org/10.1001/jamaoncol.2015.1145.

[15] Kocher M, Soffieti R, Abacioglu U, Villa S, Fauchon F, Baurnett BC, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22921-22901 study. J Clin Oncol 2011;29:124–41. https://doi.org/10.1200/JCO.2010.30.1655.

[16] Mulvania N, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, et al. Development and validation of a prognostic nomogram for melanoma patients with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet 2016;388:2004–14. https://doi.org/10.1016/S0140-6736(16)30783-2.